|
US6531455B1
(en)
*
|
1995-03-24 |
2003-03-11 |
The Regents Of The University Of California |
Delivery of polynucleotides by secretory gland expression
|
|
US5885971A
(en)
*
|
1995-03-24 |
1999-03-23 |
The Regents Of The University Of California |
Gene therapy by secretory gland expression
|
|
US20020037867A1
(en)
*
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
AU4645697A
(en)
|
1996-09-11 |
1998-04-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aav4 vector and uses thereof
|
|
US6797505B2
(en)
*
|
1998-05-27 |
2004-09-28 |
Cell Genesys, Inc. |
Recombinant AAV vectors for gene therapy of hemophilia A
|
|
DE69939169D1
(de)
*
|
1998-05-28 |
2008-09-04 |
Us Gov Health & Human Serv |
Aav5 vektoren und deren verwendung
|
|
US6984517B1
(en)
|
1998-05-28 |
2006-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector and uses thereof
|
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
CA2364417C
(en)
*
|
1999-02-19 |
2013-11-05 |
Matthew John During |
Peroral gene therapy of diabetes and obesity
|
|
WO2000074688A1
(en)
*
|
1999-06-08 |
2000-12-14 |
The Children's Hospital Of Philadelphia |
Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
|
|
US6610906B1
(en)
*
|
1999-06-09 |
2003-08-26 |
The Regents Of The University Of Michigan |
Nucleotide sequences for gene regulation and methods of use thereof
|
|
WO2001049118A1
(en)
*
|
2000-01-03 |
2001-07-12 |
Panagenic International, Inc. |
Compositions comprising genome segments and methods of using the same
|
|
US6855314B1
(en)
|
2000-03-22 |
2005-02-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector for transducing brain cells and lung cells
|
|
AU6814901A
(en)
*
|
2000-06-01 |
2001-12-11 |
Univ North Carolina |
Methods and compounds for controlled release of recombinant parvovirus vectors
|
|
US20020106381A1
(en)
*
|
2000-06-13 |
2002-08-08 |
High Katherine A. |
Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
|
|
WO2002040544A2
(en)
*
|
2000-11-14 |
2002-05-23 |
Board Of Regents, University Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
|
US6794376B2
(en)
*
|
2000-12-06 |
2004-09-21 |
William Beaumont Hospital |
Methods and compositions for enhancing diffusion of therapeutic agents through tissue
|
|
US20020159978A1
(en)
*
|
2001-02-06 |
2002-10-31 |
James Allen |
Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
|
|
EP1418810A4
(en)
|
2001-08-03 |
2006-08-02 |
Us Gov Health & Human Serv |
ORAL TREATMENT OF HEMOPHILIA
|
|
EP2518142B1
(en)
|
2001-08-24 |
2015-07-15 |
UVic Industry Partnerships Inc. |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
|
|
US20030198620A1
(en)
*
|
2002-04-16 |
2003-10-23 |
Keiya Ozawa |
Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
|
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
|
US20040092008A1
(en)
*
|
2002-11-12 |
2004-05-13 |
Snyder Richard O. |
Recombinant AAV vectors for gene therapy of hemophilia A
|
|
WO2005017101A2
(en)
|
2003-05-19 |
2005-02-24 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Avian adenoassociated virus (aaav) and uses thereof
|
|
PL2657248T3
(pl)
|
2003-06-19 |
2017-09-29 |
Genzyme Corporation |
Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
|
|
WO2005056807A2
(en)
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
|
WO2005077333A2
(en)
*
|
2004-02-10 |
2005-08-25 |
University Of Florida Research Foundation, Inc. |
Gel-based delivery of recombinant adeno-associated virus vectors
|
|
US7722596B2
(en)
*
|
2004-02-26 |
2010-05-25 |
Osprey Medical, Inc. |
Regional cardiac tissue treatment
|
|
ES2436741T3
(es)
|
2004-09-22 |
2014-01-07 |
St. Jude Children's Research Hospital |
Expresión mejorada de Factor IX en vectores de terapia génica
|
|
EP1828390B1
(en)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
WO2006089340A2
(en)
*
|
2005-02-23 |
2006-08-31 |
V-Kardia Pty Ltd |
Polynucleotide delivery to cardiac tissue
|
|
US8283151B2
(en)
|
2005-04-29 |
2012-10-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
|
|
US8152786B2
(en)
*
|
2006-11-07 |
2012-04-10 |
Osprey Medical, Inc. |
Collection catheter and kit
|
|
US9050400B2
(en)
*
|
2008-08-12 |
2015-06-09 |
Osprey Medical, Inc. |
Remote sensing catheter system and methods
|
|
US20100041984A1
(en)
*
|
2008-08-12 |
2010-02-18 |
James Edward Shapland |
Impedance sensing device and catheter system
|
|
EP2396343B1
(en)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
FR2952374B1
(fr)
*
|
2009-11-06 |
2012-11-16 |
Univ Claude Bernard Lyon |
Production de facteur ix recombinant dans une lignee cellulaire hepatocytaire humaine
|
|
US9724400B2
(en)
|
2009-11-09 |
2017-08-08 |
The Trustees Of The University Of Pennsylvania |
Administration of plant expressed oral tolerance agents
|
|
KR20130028044A
(ko)
*
|
2009-12-08 |
2013-03-18 |
헬스 리서치 인코포레이티드 |
보조제로서 퍼옥시레독신1 (ｐｒｘ１)을 사용하는 방법 및 조성물
|
|
US9295816B2
(en)
*
|
2009-12-09 |
2016-03-29 |
Osprey Medical, Inc. |
Catheter with distal and proximal ports
|
|
EP2529020B1
(en)
|
2010-01-28 |
2018-04-25 |
The Children's Hospital of Philadelphia |
A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
|
|
EP2627665B1
(en)
|
2010-10-12 |
2015-12-16 |
The Children's Hospital Of Philadelphia |
Methods and compositions for treating hemophilia B
|
|
KR20220025112A
(ko)
|
2011-06-08 |
2022-03-03 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
|
ES2664844T3
(es)
|
2011-06-20 |
2018-04-23 |
Mount Sinai School Of Medicine |
Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
|
|
EP2741804B1
(en)
|
2011-08-11 |
2017-04-26 |
Osprey Medical Inc. |
Systems and methods for limb treatment
|
|
WO2015006743A1
(en)
*
|
2013-07-12 |
2015-01-15 |
The Children's Hospital Of Philadelphia |
Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies
|
|
US10612041B2
(en)
|
2014-03-21 |
2020-04-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genome editing without nucleases
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
US11015174B2
(en)
*
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
|
CN109804432B
(zh)
|
2016-04-15 |
2023-07-14 |
武田药品工业株式会社 |
提供药代动力学药物给药方案的方法和设备
|
|
US10896749B2
(en)
|
2017-01-27 |
2021-01-19 |
Shire Human Genetic Therapies, Inc. |
Drug monitoring tool
|
|
TWI753168B
(zh)
|
2017-05-22 |
2022-01-21 |
日商武田藥品工業股份有限公司 |
用於血友病ｂ基因療法之編碼具有增強表現的重組ｆｉｘ變異體之病毒載體
|
|
WO2019083171A2
(ko)
|
2017-10-26 |
2019-05-02 |
주식회사 큐로진생명과학 |
솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물
|
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
|
GB201813528D0
(en)
|
2018-08-20 |
2018-10-03 |
Ucl Business Plc |
Factor IX encoding nucleotides
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|